Continuous renal replacement therapy (CRRT) after stem cell transplantation. A report from the prospective pediatric CRRT Registry Group

Pediatric stem cell transplant (SCT) recipients commonly develop acute renal failure (ARF). We report the demographic and survival data of pediatric SCT patients enrolled in the Prospective Pediatric Continuous Renal Replacement Therapy (ppCRRT) Registry. Since 1 January 2001, 51/370 (13.8%) patients entered in the ppCRRT Registry had received a SCT. Median age was 13.63 (0.53–23.52) years. The primary reasons for the initiation of continuous renal replacement therapy (CRRT) were treatment of fluid overload (FO) and electrolyte imbalance (49%), FO only (39%), electrolyte imbalance only (8%) and other reasons (4%). The CRRT modalities included continuous veno-veno hemodialysis (CVVHD), 43%, continuous veno-veno hemofiltration (CVVH), 37% and continuous veno-veno hemodiafiltration (CVVHDF), 20%. Seventy-six percent had multi-organ dysfunction syndrome (MODS), 72% received ventilatory support and the mean FO was 12.41 ± 3.70%. Forty-five percent of patients survived. Patients receiving convective therapies had better survival rates (59% vs 27%, P < 0.05). Patients requiring ventilatory support had worse survival (35% vs 71%, P < 0.05). Mean airway pressure (Paw) at the end of CRRT was lower in survivors (8.7 ± 2.94 vs 25.76 ± 2.03 mmH₂O, P < 0.05). Development of high mean airway pressure in non-survivors is likely related to non-fluid injury, as it was not prevented by early and aggressive fluid management by CRRT therapy.     

持续肾替代治疗在肝移植术后急性肾损伤的应用

目的 探讨持续肾替代治疗(CRRT)对肝移植术后急性肾损伤的治疗效果.方法 回顾性分析82例肝移植围手术期应用CRRT患者的肾功能情况,对其治疗前后的主要指标进行检测.结果 与治疗前比较,治疗后患者丙氨酸氨基转移酶(ALT)、总胆红素(TBil)、血尿素氮(BUN)、肌酐(Cr)、肌酸磷酸激酶(CPK)、C反应蛋白(CPR)、肌酐下降,差异均有统计学意义(P＜0.05).与治疗前比较,CRRT治疗后患者血K+、Na+、Cl-、HCO3-、中心静脉压(CVP)显著好转,差异亦具有统计学意义(P＜0.05).其他生化指标与治疗前比较变化不大,差异无统计学意义(P＞0.05).对开始血滤治疗的时机进行研究显示,在急性肾损伤RIFLE分级Ⅰ级开始血滤治疗的患者肾功能恢复的比例明显高于在F级开始血滤治疗的患者(P＜0.05).结论 CRRT治疗能明显改善肝移植术后急性肾损伤患者的预后.     

急性肝功能衰竭患者肝移植术后急性肾功能衰竭的病因分析及综合治疗

目的 分析急性肝功能衰竭(acute liver failure,ALF)患者肝移植术后肾功能衰竭的原因,评价以持续肾脏替代治疗(continuous renal replacement therapy,CRRT)为基础的综合疗法的疗效.方法 回顾性分析2001年1月至2006年6月在我院施行的412例肝移植资料,根据UNOS肝功能分级标准筛选出54例ALF患者(UNOS1和2A),其中17例移植术后出现急性肾功能衰竭(acute renal failure,ARF).在CRRT治疗基础上,进行抗排斥、抗感染、营养支持等治疗,并对患者围手术期情况、术后并发症、死亡原因及随访结果进行了分析.结果 CRRT治疗过程中无并发症发生.无ARF组围手术期死亡率为5.4%,术后并发症发生率为35.1%,1、3年生存率分别为89.2%和81.1%.ARF组围手术期死亡率为58.8%,术后并发症发生率为100%,1、3年生存率分别为41.2%和41.2%.结论 肝移植效果主要取决于肝外器官功能和术前肝功能状态.ALF患者围手术期死亡率较高,其中术前血肌酐高术后出现ARF率高,死亡率更高.以CRRT为基础的综合疗法能有效治疗ARF患者.     

Dialysis and pediatric acute kidney injury: choice of renal support modality

Dialytic intervention for infants and children with acute kidney injury (AKI) can take many forms. Whether patients are treated by intermittent hemodialysis, peritoneal dialysis or continuous renal replacement therapy depends on specific patient characteristics. Modality choice is also determined by a variety of factors, including provider preference, available institutional resources, dialytic goals and the specific advantages or disadvantages of each modality. Our approach to AKI has benefited from the derivation and generally accepted defining criteria put forth by the Acute Dialysis Quality Initiative (ADQI) group. These are known as the risk, injury, failure, loss, and end-stage renal disease (RIFLE) criteria. A modified pediatrics RIFLE (pRIFLE) criteria has recently been validated. Common defining criteria will allow comparative investigation into therapeutic benefits of different dialytic interventions. While this is an extremely important development in our approach to AKI, several fundamental questions remain. Of these, arguably, the most important are “When and what type of dialytic modality should be used in the treatment of pediatric AKI?” This review will provide an overview of the limited data with the aim of providing objective guidelines regarding modality choice for pediatric AKI. Comparisons in terms of cost, availability, safety and target group will be reviewed.     

Treatment of acute renal failure in an infant by continuous arteriovenous hemodialysis

Continuous arteriovenous hemodialysis (CAVHD) was performed in a critically ill, oliguric infant with progressive uremia using a miniature Amicon hemofilter. Modification was made in the filter system by circulating 2.5% Dianeal peritoneal dialysis fluid into the second port of the ultrafiltrate compartment to enable the filter to function by dialysis too (CAVHD). In comparison with continuous arteriovenous hemofiltration (CAVH), CAVHD provided superior urea clearance and adequate fluid removal, allowing the simultaneous administration of parenteral nutrition. The higher solute clearances in CAVHD make the technique superior to CAVH for renal replacement therapy in critically ill infants.     

Challenges in diagnosing acute pancreatitis in renal transplant patients

Abstract: Acute pancreatitis is a recognized occurrence in patients with end‐stage renal disease, those on dialysis and those who have undergone renal transplantation. The incidence is significantly increased in comparison to the general population and carries significant mortality. We report two cases of acute pancreatitis that occurred in stable renal transplant recipients, and in which there was diagnostic difficulty. The etiology of the acute pancreatitis is not always identifiable in these patients. Classical symptoms and laboratory findings are often absent, which may cause diagnostic difficulty. Our experience suggests that in immunosuppressed patients with unexplained abdominal pain or abnormal liver function tests, acute pancreatitis should be considered at an early stage in order to initiate appropriate treatment and therefore minimize mortality and morbidity.     

Poor prognosis of heart transplant patients with end-stage renal failure.

BACKGROUND: Chronic kidney disease (CKD) and end-stage renal failure (ESRF) are major complications after a heart transplant. The aim of this study is to compare survival in heart transplant (HT) vs non-heart transplant (non-HT) patients starting dialysis. METHODS: Survival was studied among the 539 newly dialysed patients between 1 January 1995 and 31 December 2005 in our Department. All patients were prospectively followed from the date of first dialysis up to death or 31 December 2005. Multivariate survival analysis adjusted on baseline characteristics was performed with the Cox model. RESULTS: There were 21 HT patients and they were younger than non-HT patients at first dialysis: 58.6+/-11.6 vs 63.0+/-16.2 years (P=0.09). Calcineurin inhibitor nephrotoxicity was the main cause of ESRF in HT patients (47.6%). Crude 1, 3 and 5-year survival rates in HT and in non-HT patients were as follows: 76.2%, 57.1%, 28.6% and 79.1%, 58.7%, 46.7% (P=0.2). The adjusted hazard ratio of death in HT vs non-HT patients was 2.27 [1.33-3.87], P=0.003. Sudden death was the main cause of death in HT patients, in 33.3% vs 10.4% in non-HT patients (P=0.01). Five HT patients benefited from renal transplant. They were all alive at the end of the study period, while one patient among the 16 remaining on dialysis survived. CONCLUSION: HT patients with CKD who reached ESRF have a poor outcome after starting dialysis in comparison with other ESRF patients. Improvement in renal function management in the case of CKD is needed in these patients and non-nephrotoxic immunosuppressive regimens have to be evaluated. Renal transplant should be the ESRF treatment of choice in HT patients.     

Development of a continuous renal replacement program in critically ill patients

BACKGROUND: Critically ill patients encounter many obstacles, such as acute renal failure, that increases length of stay as well as hospital cost. Dialysis in these patients is often ineffective thereby prolonging the inevitable and significantly increasing the cost of care. A dialysis program that could improve patient care, potentially improve outcome and be "revenue neutral" would be ideal. METHODS: A continuous renal replacement therapy (CRRT) program was developed to significantly impact the care of critically ill patients Using the latest CRRT equipment along with an innovative hands-on CRRT training program, a specialized CRRT team was created. Working in conjunction with the hospital business office, new revenue charge codes were created and existing codes were updated. Patients who underwent CRRT had their financial records reviewed for: hospital cost to perform CRRT, total hospital billing to the payer, CRRT revenue 881 (billing units) charged to the payer, total charges and reimbursement for the account, percentage of reimbursement, collected revenue, and payer. RESULTS: From April 2000 to February 2002, 39 critically ill patients underwent CRRT. Initial set-up cost was US$79,622.80 and the cost of CRRT was US$222,323.98. The hospital billed for US$656,090.63 and assuming 100% reimbursement, the potential profit was US$427,678.50. However, loss of revenue, mainly from noncompliance with charge capture resulted in the hospital billing only US$386,794.32 with a total reimbursement of US$165,779.86. The 21 burn patients who underwent CRRT yielded a net profit of US$10,294.12, with the highest reimbursement from workman's compensation and private payers. The overall mortality rate was 59% and 65% for the burn patients; significantly lower than published national averages. CONCLUSIONS: An in-house CRRT program improved patient care by providing dialysis in patients who normally would not tolerate the procedure. Although there was a loss of revenue, CRRT in the burn patients appeared "revenue neutral." Although not specifically studied in this review, based on published data, mortality rates in this population were lower than expected especially in critically ill burn patients.     

连续性肾脏替代与间歇性血液透析治疗急性肾功能衰竭的生存率分析

目的 探讨连续性肾脏替代与间歇性血液透析治疗急性肾功能衰竭的生存率分析.方法 按照纳入标准搜集国内运用连续性肾脏替代和间歇性血液透析对比治疗急性肾功能衰竭的文献.使用Rev Man 5.0统计软件完成Meta分析,以SAS 8.0软件计算失安全系数.结果 按照纳入标准及排除标准,最后纳入6篇文献,包括受试患者476例进...     

Overview of pediatric renal replacement therapy in acute renal failure

The disease spectrum leading to pediatric renal replacement therapy (RRT) provision has broadened over the last decade. In the 1980s, intrinsic renal disease and burns constituted the most common pediatric acute renal failure etiologies. More recent data demonstrate that pediatric acute renal failure (ARF) most often results from complications of other systemic diseases, resulting from advancements in congenital heart surgery, neonatal care, and bone marrow and solid organ transplantation. In addition, RRT modality preferences to treat critically ill children have shifted from peritoneal dialysis to continuous renal replacement therapy (CRRT) as a result of improvements in CRRT technologies. Currently, multicenter prospective outcome studies for critically ill children with ARF are sorely lacking. The aims of this article are to review the pediatric specific causes necessitating renal replacement therapy provision, with an emphasis on emerging practice patterns with respect to modality and the timing of treatment, and to focus upon the application of the different renal replacement therapy modalities and assessment of the outcome of children with ARF who receive renal replacement therapy.     

胎肾细胞移植治疗急性肾功能衰竭的动物实验研究

进行了胎肾细胞移植治疗二氯化汞造成的动物实验。致死量组：细胞移植组平均存活４．２８天，对照组存活３．０２天；重中毒量组：１２０小时细胞移植组平均ＢＵＮ１０．６ｍｍｏｌ／Ｌ，Ｃｒ２２９μｍｏｌ／Ｌ，放射性核素每分钟闪烁计数３３７８ｒ／ｍｉｎ，对照组：ＢＵＮ３２．７ｍｍｏｌ／Ｌ，Ｃｒ８２９μｍｏｌ／Ｌ，ｃｐｍ值１３７３ｒ／ｍｉｎ；中毒量组；细胞移植组ＢＵＮ７．８ｍｍｏｌ／Ｌ，ｃＲ１６７．５μＭＯＬ／ｌ     

妊娠合并急性肾衰竭的临床分析

目的探讨妊娠合并急性肾衰竭ARF）诊治。方法回顾性分析24例妊娠并急性肾衰竭患者的临床资料。结果24例患者中22例患者治愈或好转出院，2例患者死亡。结论早期诊断、积极治疗妊娠合并急性肾衰竭，可以挽救母婴生命。治疗措施包括：适时终止妊娠、早期透析、积极治疗原发病、防治感染。     

连续性肾脏替代治疗剂量对急性肾衰竭患者预后影响的荟萃分析

目的 通过荟萃分析评价连续性肾脏替代治疗（CRRT）剂量对急性肾衰竭（ARF）患者预后的影响。 方法 制定原始文献的纳入标准和检索策略,在Medline、EMBASE及Cochrane 图书馆内进行相关的检索。比较标准剂量和低剂量CRRT对ARF患者预后影响的随机对照试验（RCT）纳入分析。应用随机或固定效应模型处理预后指标的相对危险度（RR）。 结果 6项研究符合纳入标准。与低剂量比较,标准剂量CRRT未能降低病死率（RR 0.87,95%CI 0.70~1.07,P = 0.19）和联合终点事件（死亡和依赖透析）的发生率（RR 0.87,95%CI 0.69~1.09,P = 0.21）,但有增加依赖透析率的趋势（RR 1.43,95%CI 0.94~2.18,P = 0.09）。由于研究间存在异质性,亚组分析显示,实际治疗剂量达标（标准剂量>35 ml&#8226;kg-1&#8226;min-1）、治疗模式以连续性静脉-静脉血液滤过（CVVH）为主（置换液量大于透析液量）、非脓毒症为ARF主要原因（脓毒血症发病率<50%）的研究中,经标准剂量CRRT后病死率显著下降（P < 0.01）。 结论 尽管标准剂量CRRT未能降低ARF患者的病死率、依赖透析率和联合终点事件的发生率,但可改善实际治疗剂量达标、治疗模式以CVVH为主及非脓毒症ARF患者的存活率。     

Effect of acute renal failure on outcome in children with severe septic shock

Acute renal failure (ARF) requiring renal replacement therapy (RRT) has been associated with an excess risk of mortality in adult patients with septic shock, but it is unknown whether this is also applicable to pediatric patients. We therefore conducted a retrospective pilot study. All children presenting with septic shock between 1st January 1998 and 1st April 2004 were analyzed. Patients with fluid refractory-dopamine resistant shock, necessitating the use of noradrenaline, were included. ARF was defined as the deterioration of renal function to the extent that renal replacement therapy was required (ARF group). This ARF group was compared with patients without ARF (non-ARF group). Out of the 22 children with severe septic shock, seven developed ARF. PIM2 and PRISM scores upon admission were comparable between both groups. Mortality rates were significantly higher in patients with ARF (57.1% vs 6.7%; p=0.02). Pediatric patients with severe septic shock developing ARF have excess mortality compared to pediatric patients who do not develop ARF, although on diagnosis, severity of underlying disease and calculated risk of mortality were comparable. A multicenter trial is necessary to confirm these findings and to determine the contribution of ARF to pediatric sepsis mortality.     

急性肾衰竭患者血清胆碱酯酶变化的意义

目的通过观察急性肾衰竭（ARF）患者血清胆碱酯酶（CHE）的变化,探讨血清CHE与ARF预后的关系,并分析其临床意义。方法将68例ARF患者分为存活组（A组）及死亡组（B组）,检测其治疗前后血清CHE,并与40例肾功能正常的原发肾小球疾病患者（M组）和30例健康体检者（N组）比较。结果A组和B组患者血清CHE均较M组和N组降低;而M组与N组间无显著性差异;A组患者治疗后血清CHE恢复,与治疗前CHE相比差异有统计学意义;B组患者治疗后血清CHE持续降低。结论血清CHE可作为ARF的检测物之一,对ARF患者的病情监测和预后判断具有重要的临床意义。     

Continuous renal replacement therapy and plasma exchange in newborns and infants

The objective of our study was to present our experience in the treatment of small children with continuous renal replacement therapy (CRRT) and plasma exchange (PE). From March 1986 to April 2000, 21 critically ill children (14 newborns and 7 infants) with acute renal failure (ARF) and multiple organ failure were treated with CRRT and PE. In the newborn group, there were 8 males and 6 females, age 15.7 +/- 11.7 days, with body weights of 3,348 +/- 585 g. In the infant group, there were 4 males and 3 females, age 118 +/- 67 days, with body weights 5,186 +/- 734 g. The indications for the beginning of CRRT and/or PE were ARF with anuria and hyperhydration (17 patients), azotemia and anuria (1 patient), hemolytic uremic syndrome (1 patient), and hyperammonemia (2 patients). In all patients, peritoneal dialysis was considered inappropriate. PE and CRRT monitors were used, double lumen 5 Fr and 7 Fr hemodialysis catheters were the vascular access, low dose heparin and prostacyclin were anticoagulants, and lactate or bicarbonate buffered replacement solutions were used predilutionally. Side events were clotting within the extracorporeal circuit, catheter malfunction, serious hypotension (6 patients), and pulmonary edema (1 patient). Ten of 21 patients (47.6%) recovered renal function and 9 of 21 patients (42.9%) survived. Survivors had fewer failing organs (3.6 +/- 0.5) than nonsurvivors (4.8 +/- 0.9) (p = 0.0008). Pump driven CRRT and PE were feasible, efficient, and safe procedures in newborns and infants. Without CRRT, it is uncertain whether any of our patients would have the chance to survive.     

连续性静脉-静脉血液滤过在腹部肿瘤术后急性肾功能衰竭中的应用

目的 探讨连续性静脉-静脉血液滤过在腹部肿瘤手术后急性肾功能衰竭中应用的临床意义.方法 对31例腹部肿瘤术后急性肾功能衰竭患者采用连续性静脉-静脉血液滤过治疗,比较治疗前、后电解质、血肌酐、尿素氮以及动脉血气分析的变化.结果 31例患者中30例存活,1例死亡.存活患者经连续性静脉-静脉血液滤过后血尿素氨和肌酐均逐渐下降直至恢复正常;经连续性静脉.静脉血液滤过后4～5 h血钾可降至正常范围;酸中毒得到纠正、动脉血氧分压明显升高,尿量分别于连续性静脉-静脉血液滤过后5～20 d恢复正常,所有患者经连续性静脉-静脉血液滤过后水肿得到明显改善.结论 连续性静脉-静脉血液滤过是治疗腹部肿瘤术后急性肾功能衰竭的一种有教、方便而安全的方法.     

A systematic review of continuous renal replacement therapy and intermittent haemodialysis in management of patients with acute renal failure

Background: Acute renal failure (ARF) still bears a poor prognosis with mortality rates up to 70% and the ideal form of renal replacement therapy (RRT) remains controversial. The purpose of this study was to conduct a systematic review and meta-analysis of all randomized controlled trials (RCT) to examine the effect of dialysis modality (IHD: Intermittent haemodialysis; CRRT: continuous renal replacement therapy) on survival of patients with ARF and to also study the effect of each modality on dialysis dependence (DD). Methods: Using and combining two comprehensive search themes (ARF and RRT), we searched electronic databases from 1969 through September of 2007, supplemented by a manual review of abstracts from nephrology meetings and reference lists of review articles. All RCT comparing IHD with CRRT in adult patients with ARF and with explicit reporting of mortality were included. The primary outcome was the pooled estimate of the odds ratio (OR) of mortality for patients with ARF treated with CRRT versus IHD. The secondary outcome was OR of DD at time of discharge for surviving patients. Results: A total of 587 studies were identified, 554 of which were excluded on initial screening. Analysis of the nine RCT (1635 patients) showed an OR of 0.89 (0.63–1.24) for survival in patients on CRRT. Limiting the analysis to the seven RCT published after the year 2000, revealed an OR of 0.72 (0.58–0.90). The OR of all the studies before 2000 was 1.06 (95% CI 0.67–1.68), as compared with OR of 0.61 (95% CI 0.50–0.74) for studies post-2000. Four studies showed a significantly lower risk of DD among the CRRT group and none showed higher OR for DD. When analysis was limited to the RCT, the OR for DD was 1.07 (0.47–2.39), suggesting no difference in DD between the modalities. Conclusions: Similar to previously reported meta-analyses, we did not find a significant effect of CRRT on the OR of survival. The progressive reduction in the OR of survival with CRRT relative to IHD might reflect progressive improvements in IHD. The OR of DD was not affected by mode of RRT. In conclusion, compared with IHD, CRRT does not offer an advantage with regards to survival or DD in ARF. Considering its cost and potential disadvantages, it is imperative to identify the subset of patients with ARF that would potentially derive maximum benefit from CRRT. This will require large, adequately powered studies with sufficient follow-up.     

肾后性急性肾功能衰竭的微创治疗

目的:总结腔内微创技术治疗肾后性急性肾功能衰竭的临床经验。方法:对48例不同梗阻原因致肾后性急性肾功能衰竭的患者,采用膀胱镜下逆行插管(3例)、输尿管镜下取石/碎石后置管(35例)引流、经皮肾穿刺造瘘引流(10例)解除梗阻,回顾性分析其治疗效果。结果:48例患者均成功解除尿路梗阻,无一例死亡,无尿瘘、输尿管穿孔、肾出血等并发症。结论:上尿路梗阻是肾后性急性肾功能衰竭的主要原因,应首选输尿管镜技术处理。如处理困难,膀胱镜下逆行插管和经皮肾镜穿刺造瘘引流也是可行的有效方法。